FDA sets July PCAC meeting to review 7 peptides for 503A list

The FDA has published a Federal Register notice scheduling a two-day Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23-24, 2026 to evaluate seven peptides for possible inclusion on the Section 503A Bulk Drug Substances List. The notice followed a significant April 22 update to the agency's significant-safety-concerns list, in which 12 peptides were removed from Category 2 — the regulatory designation that had effectively prohibited their compounding since 2023.

What happened

Effective April 22, 2026, the FDA updated its bulk drug substances list to remove 12 peptides from Category 2, the "significant safety concerns" designation that had blocked licensed compounding pharmacies from preparing them under Section 503A. The 12 substances removed are: BPC-157, KPV, MOTs-C, TB-500, Emideltide (DSIP), Epitalon, Semax, Cathelicidin LL-37, Dihexa Acetate, GHK-Cu, PEG-MGF, and Melanotan II.

The FDA made clear that removal from Category 2 does not represent a safety determination or approval. The designations were withdrawn because the original nominations that had placed them in Category 2 were retracted, not because the agency concluded the compounds are safe. Until the PCAC process concludes and FDA issues final rulemaking, none of these substances can be legally compounded under 503A.

Seven of the twelve will go before the advisory committee first, split across two days. On July 23, the committee will review BPC-157, KPV, TB-500, and MOTs-C. On July 24, the focus shifts to Emideltide (DSIP), Semax, and Epitalon. A second PCAC meeting covering the remaining five substances is expected in early 2027.

The meeting will be held at FDA's White Oak Campus in Silver Spring, Maryland, with a virtual attendance option. The docket number for public submissions is FDA-2026-N-2979.

Why it matters

For most of the strength and recovery peptide community, this is the most consequential regulatory development since the original 503A Category 2 designations took effect. Those designations closed the primary legal channel for patient-specific compounded peptides starting in 2023.

A positive PCAC recommendation does not automatically restore compounding access — the FDA still needs to finalize rulemaking — but it would represent the clearest pathway in years toward legal, pharmacy-prepared formulations. Compounded peptides produced through licensed 503A pharmacies operate under physician prescription, sterile manufacturing standards, and quality controls that the gray research-chemical market does not require.

The April Category 2 removals followed a February 2026 announcement from HHS Secretary Robert F. Kennedy Jr., who signaled that approximately 14 of the 19 originally restricted peptides were expected to move toward restored compounding access. The PCAC process is how that move happens procedurally.

What to watch

• Whether PCAC recommends 503A listing for any of the seven peptides, and under what conditions
• Whether the committee requests additional safety or pharmacokinetic data as a condition of recommendation
• The comment record: public submissions from physicians, pharmacists, patients, and compounders may affect how the committee frames its review — comments submitted by July 9, 2026 reach the committee directly
• The second PCAC meeting (early 2027) covering the remaining five substances, including LL-37 and GHK-Cu
• FDA's final rulemaking timeline after any positive recommendations

Sources

• Federal Register — PCAC Meeting Notice (Docket FDA-2026-N-2979)
• HealingMaps — FDA to Review 7 Peptides in July 2026
• National Law Review — FDA to Consider Lifting Restrictions on Compounded Peptides
• Fierce Pharma — FDA Reclassifies 12 Unapproved Peptides